HolundB. Latent prostatic cancer in a consecutive autopsy series. Scand J Urol Nephrol. 1980;14:29–35.
2.
SakrWAHaasGPCassinBFPontesJECrissmanJD. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol. 1993;150:379–385.
3.
Gallardo-WilliamsMTMaronpotRRWineRNBrunssenSHChapinRE. Inhibition of enzymatic activity of prostate-specific antigen by boric acid and 3-nitrophenyl boronic acid. Prostate. 2003;54:44–49.
4.
CohenPGravesHCPeehlDM, Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab. 1992;75:1046–1053.
5.
CohenPPeehlDMGravesHCRosenfeldRG. Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J Endocrinol. 1994;142:407–415.
6.
D'AmicoAVChenMHRoehlKACatalonaWJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004;351:125–135.
7.
AnsariMSGuptaNP. A comparison of lycopene and orchidectomy vs orchidectomy alone in the management of advanced prostate cancer. Br J Urol Int. 2003;92:375–378.
8.
AnsariMSGuptaNP. Lycopene: A novel drug therapy in hormone refractory metastatic prostate cancer. Urol Oncol. 2004;22:415–42.
9.
Gallardo-WilliamsMTChapinREKingPE, Boron supplementation inhibits the growth and local expression of IGF-1 in human prostate adenocarcinoma (LNCaP) tumors in nude mice. Toxicol Pathol. 2004;32:73–78.
10.
BarrancoWTEckhertCD. Boric acid inhibits human prostate cancer cell proliferation. Cancer Lett. 2004;8:21–29.
11.
CuiYWintonMIZhangZF, Dietary boron intake and prostate cancer risk. Oncol Rep. 2004;11:887–892.
12.
YamaguchiKUzzoRGPimkinaI, Methylseleninic acid sensitizes prostate cancer cells to TRAIL-medicated apoptosis. Oncogene. 2005;24:5868–5877.
13.
PezzatoESartorLDell'AicaI, Prostate carcinoma and green tea: PSA-triggered basement membrane degradation and MMP-2 activation are inhibited by (—)epigallocatechin-3-gallate. Int J Cancer. 2004;112:787–792.
14.
DalaisFSMelialaAWattanapenpaiboonN, Effects of a diet rich in phytoestrogens on prostate-specific antigen and sex hormones in men diagnosed with prostate cancer. Urology. 2004;64:510.
15.
DeebDXuYXJiangH, Curcumin (diferuloyl-methane) enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in LNCaP prostate cancer cells. Mol Cancer Ther. 2003;2:95–103.
16.
DeebDJiangHGaoX, Curcumin sensitizes prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L by inhibiting nuclear factor kappaB through suppression of Ikappa-Balpha phosphorylation. Mol Cancer Ther. 2004;3:803–812.
17.
DoraiTDutcherJPDempsterDWWiernikPH. Therapeutic potential of curcumin in prostate cancer-V: Interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cells. Prostate. 2004;60:1–17.
18.
ChendilDRangaRSMeigooniESathish-KumarSAhmedMM. Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3. Oncogene. 2004;23:1599–1607.
BergesRRKassenASengeT. Treatment of symptomatic benign prostatic hyperplasia with beta-sitosterol: An 18-month follow-up. Br J Urol Int. 2000;85:842–846.
21.
von HoltzRLFinkCSAwadAB. Beta-Sitosterol activates the sphingomyelin cycle and induces apoptosis in LNCaP human prostate cancer cells. Nutr Cancer. 1998;32:8–12.
22.
AwadABFinkCSWilliamsHKimU. In vitro and in vivo (SCID mice) effects of phytosterols on the growth and dissemination of human prostate cancer PC-3 cells. Eur J Cancer Prev. 2001;10:507–513.
23.
AwadABBurrATFinkCS. Effect of resveratrol and beta-sitosterol in combination on reactive oxygen species and prostaglandin release by PC-3 cells. Prostaglandins Leukot Essent Fatty Acids. 2005;72:219–226.
